Scribe Therapeutics.
genetic medicine therapeutics company from Alameda, California
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
Earlier this month
-
CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.Some support1 report
-
Scribe Therapeutics secured funding through a private placement with Sanofi and received grant support from CIRM.Some support1 report
One to three months ago
-
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.Some support2 reports
-
Scribe Therapeutics' shares are set to begin trading on Nasdaq, following an analysis of IPO trends by HSBC.Some support2 reports
-
Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Scribe Therapeutics this week
News at the entities that move Scribe Therapeutics most-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Scribe Therapeutics
-
Eli Lilly and Company StructuralExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Scribe Therapeutics
-
Wells Fargo TransactionalWells Fargo upgraded Sweetgreen stock to overweight from equal weight on September 28, 2026.Moves Scribe Therapeutics
-
Leerink partners OperationalAnalyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Moves Scribe Therapeutics
-
Sanofi TransactionalSanofi and the Association of Science and Technology Centers announced a partnership focused on environmental education.Moves Scribe Therapeutics
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Scribe Therapeutics
Connections
The 11 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Scribe Therapeutics is scheduled to begin trading its shares on the Nasdaq exchange.
-
Andreessen Horowitz Structural
Andreessen Horowitz is identified as a major shareholder of Scribe Therapeutics.
-
Eli Lilly and Company Structural
Eli Lilly provides financial backing for Scribe Therapeutics.
-
Wells Fargo Transactional
Wells Fargo assigned an overweight rating to Scribe Therapeutics.
-
Securities and Exchange Commission Structural
Scribe Therapeutics initiated contact with the SEC regarding plans to achieve public market status.
-
Leerink partners Operational
Leerink Partners actively influenced Scribe Therapeutics by leading its IPO and providing market ratings.
-
CRISPR Therapeutics Operational
The two companies are actively competing against each other in the gene-editing therapeutics market.
-
Yanan Zhu Structural
Yanan Zhu serves as an analyst covering Scribe Therapeutics for Wells Fargo.
Show all 11 connections
History
Events by the month they beganSeptember 2026
2 eventsJuly 2026
3 events- Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
- Scribe Therapeutics' shares are set to begin trading on Nasdaq, following an analysis of IPO trends by HSBC.
- Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.